RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | -227.23 | -421.14 | 46.84 |
| FCF Yield | -0.05% | -0.04% | -0.02% | -0.06% |
| EV / EBITDA | -1,423.20 | 39,596.81 | -5,015.90 | -1,468.13 |
| Quality | ||||
| ROIC | 1,654.75% | -145.94% | -570.86% | -241.15% |
| Gross Margin | 100.00% | 91.35% | 93.59% | 99.91% |
| Cash Conversion Ratio | 0.54 | 0.62 | 0.66 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.00% | -0.00% | 3.29% | 10.66% |
| Free Cash Flow Growth | 5.01% | 1.65% | 11.52% | -28.11% |
| Safety | ||||
| Net Debt / EBITDA | -0.82 | -1.19 | -0.46 | -0.08 |
| Interest Coverage | -4.31 | -4.09 | -5.57 | -8.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,499.01 | -2,916.44 | -244,865.68 |